Therapeutic Asset Ratings
435 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cobimetinib
Pancreatic Adenocarcinoma
OHSU Knight Cancer Institute
P1/2
CCC
(52)
Everolimus
Acute Myeloid Leukemia
OHSU Knight Cancer Institute
P1/2
CCC
(51)
Vinorelbine
Metastatic Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(51)
Zn-C3
Primary Peritoneal Carcinoma
OHSU Knight Cancer Institute
P1/2
CCC
(51)
Abemaciclib
Ovarian Cancer
OHSU Knight Cancer Institute
P2
CCC
(50)
Entrectinib
Ovarian Cancer
OHSU Knight Cancer Institute
P2
CCC
(50)
Gdc-0449
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CCC
(50)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CCC
(50)
Regorafenib
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CCC
(50)
TANCIN
Pancreatic Neoplasm
OHSU Knight Cancer Institute
P2
CCC
(50)
Trastuzumab Emtansine
Plasma Cell Myeloma
OHSU Knight Cancer Institute
P2
CCC
(50)
Vinorelbine
Acute Myeloid Leukemia
OHSU Knight Cancer Institute
P2
CCC
(50)
Capecitabine
Sarcoma
OHSU Knight Cancer Institute
P1
CCC
(50)
FULVESTRANT
Pancreatic Cancer for Phase II
OHSU Knight Cancer Institute
P1
CCC
(50)
Niraparib
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer Institute
P1
CCC
(50)
Atezolizumab
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(50)
Niraparib
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1/2
CCC
(50)
gsk1120212
Prostate Cancer
OHSU Knight Cancer Institute
P2
CCC
(49)
Capecitabine
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CCC
(49)
Irinotecan
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P1
CCC
(49)
TRASTUZUMAB
Stage II Pancreatic Cancer AJCC v8
OHSU Knight Cancer Institute
P1
CCC
(49)
EXEMESTANE
Prostate Cancer
OHSU Knight Cancer Institute
P2
CCC
(48)
Entrectinib
Breast Carcinoma
OHSU Knight Cancer Institute
P1
CCC
(48)
TRASTUZUMAB
Malignant Pancreatic Neoplasm
OHSU Knight Cancer Institute
P1
CCC
(48)
VEMURAFENIB
Breast Carcinoma
OHSU Knight Cancer Institute
P1
CCC
(48)
Showing 276 to 300 of 435 assets
Previous
Page 12 of 18
Next